SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PharmaPrint (PPRT) -- Ignore unavailable to you. Want to Upgrade?


To: JB who wrote (20)3/11/1999 11:04:00 AM
From: Harry J.  Respond to of 48
 
JB - I clicked on the SI "news" button this AM and got this:

"IRVINE, Calif.--(BUSINESS WIRE)--March 11, 1999--PharmaPrint Inc. (Nasdaq:PPRT) Thursday announced that it recently completed a clinical trial of PPRT-321, a pharmaceutical candidate derived from saw palmetto, that demonstrated that the product was safe and appeared to improve symptoms associated with an enlarged prostate gland." [MORE]

I haven't checked the SEC's Edgar dbase lately to see how the registration and sale of restricted stock is going. It could be that the stock price pressure lately in the face of no-to-good news has been from that sale.
Harry



To: JB who wrote (20)6/24/1999 5:13:00 PM
From: blankmind  Read Replies (1) | Respond to of 48
 
PPRT's results aren't too bad

- you'll see that sales are growing at a good clip; while R&D & overhead remain steady

- the other big expense - R&D - is high - but as long as they roll out the products - we're okay